To the Editor:
Gene deletions are common events in various hereditary diseases, but conventional PCR often fails to detect such defects in heterozygous patients (1 ) . This highlights the need for a suitable method, easily applicable in a diagnostic laboratory (2 ) . Large deletions account for ϳ5% of cases of hemophilia, inherited as a recessive X-linked disease, making determination of carrier status difficult. It is of particular importance when a pregnant woman is carrying a male fetus. Prenatal testing that uses invasive methods of sample collection carries a risk of miscarriage or fetal injury, and is unnecessary if the woman is not a carrier. We designed a real-time quantitative PCR assay to establish heterozygous status for deletion carriers and to avoid such risky situations in a family in which a large deletion of the F9 gene was responsible for a severe form of hemophilia B.
After receiving informed consent, we prepared genomic DNA from a hemophiliac person and two females, a niece and a first cousin, from 200 L of EDTA blood, using the High Pure PCR Template Preparation Kit (Roche Applied Science), according to the recommendations of the manufacturer.
Part of exon h of the F9 gene (Xq27) and part of exon 1 (used as reference) of the ␤-globin gene (11p15) were amplified by real-time PCR from DNA obtained from the propositus, the two related female patients, unaffected males (n ϭ 5), and female noncarriers (n ϭ 6). Relative quantification was established by comparison with a range of serial dilutions of the female DNA. The sequences for the primers (MWG) are as follows: F9 forward, 5Ј-GT-CAGTGGTCCCAAGTAGTC-3Ј; F9 reverse, 5Ј-AAGACATGTGGCTCG-GTCAA-3Ј; ␤-globin forward, 5Ј-TGCCAGAAGAGCCAAGGACA-3Ј; ␤-globin reverse, 5Ј-CTCACCAC-CAACTTCATCCAC-3Ј. The primers were located in coding sequences if possible, avoiding the risk of reduced PCR efficiency attributable to a mismatch with the target sequence.
The reactions were carried out in a LightCycler instrument (Roche), with a reaction volume of 20 L, using the FastStart DNA Master SYBR Green I ® Kit (Roche), 3 mM MgCl 2 , 0.5 M each primer, 50 ng of patient or control DNA, and 100, 20, and 4 ng of calibrators. PCR conditions were as follows : 95°C for 8 min, 95°C for 10 s, 60°C for 10 s, and 72°C for 15 s (45 cycles). Melting curve analysis was performed after PCR. Two calibration curves for each gene were generated with the female DNA calibrator. These curves were used to quantify unknown samples, and a F9:␤-globin concentration ratio was calculated. The results are summarized in Table 1 .
As expected, the F9 gene copy number was correctly determined in control groups because it was two times higher in females than in males, demonstrating the reliability of the method to detect patients heterozygous for deletions because unaffected male samples mimic carriers for the gene deletion. Results in these two groups did not overlap, and the CV of the assay was 15% and 10% for the normal (two copies) or the deleted (one copy) samples, respectively. The first-cousin woman was pregnant, and she was carrying a male fetus. She was diagnosed as a carrier for the deletion by the gene dosage assay. The prenatal diagnosis, performed by amniocentesis, revealed that the fetus was affected, thus confirming the direct molecular determination of her status and the reliability of the method. When the method was applied for the niece, it revealed a normal result, establishing her noncarrier status.
The proposed rapid real-time PCR assay has several advantages. Realtime quantitative PCR using labeled probes has already been described, but the use of such probes, because the anomaly is often family specific, is particularly expensive (3, 4 ) . Our strategy does not require specific hybridization probes and can avoid this additional cost. Because most of the deletions occurring in the F9 gene remove at least exon h, the assay was targeted to this region, and it can be applied to families in which F9 gene deletions are responsible for the disease. Furthermore, the method can be rapidly adapted to other genetic diseases. Apolipoprotein A-IV in the Fed and Fasting States
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To the Editor: Apolipoprotein A-IV (apo A-IV) is a 46-kDa plasma protein (1 ) with different isoforms (2 ). It is secreted with chylomicrons into the circulation (3 ).
Within the plasma compartment, apo A-IV dissociates from chylomicrons (4 ) and associates with HDL, triglyceride-rich lipoproteins, and the lipoprotein-free fraction (5 ).
Apo A-IV is influenced by dietary intervention, and a low-fat, low-cholesterol diet (NCEP Step II diet) and is able to decrease apo A-IV secretion rates significantly (6 ) . Apo A-IV is catabolized rapidly with a fractional catabolic rate of ϳ2.4 pools/day (7 ). Apo A-IV is higher in patients with renal impairment (8 ) . In ad-libitumfed rats, serum apo A-IV concentrations showed a circadian rhythm associated with the feeding pattern (9 ) . The role of apo A-IV as a risk indicator in coronary artery disease is currently unclear. Some studies have shown that apo A-IV concentrations are lower in patients with coronary artery disease (10 ), indicating that apo A-IV is an antiatherogenic protein. However, some questions remain unanswered because apo A-IV is also closely linked to several highly atherogenic situations in humans. For example, high triglyceride concentrations, renal impairment, or fat-enriched diets cause an increase in apo A-IV concentrations.
Because apo A-IV is linked to triglyceride concentrations, we were interested to study apo A-IV concentrations in the fasting and nonfasting state. We studied 28 normolipidemic healthy persons (13 men and 15 women; mean age, 30 years) with normal body weight for 24 h in the fasting and nonfasting states. Apo A-IV and lipoprotein concentrations were determined every 3 h for a total of 24 h by standard techniques as described recently (11 ). Each study sequence started at 0700 in the morning. For the fasting group, members were asked to skip their usual breakfast and remained fasting for at least 24 h. In contrast, for the nonfasting group, members were permitted to follow their typical food intake during the study. During prolonged fasting, the apo A-IV concentration decreased to ϳ50% of the starting concentration, from a mean (SD) of 150 (37) to 84 (26) mg/L (Fig. 1) . Triglycerides decreased slightly, reaching a plateau within 6 -12 h [decrease from 910 (370) to 750 (220) mg/L]. In the nonfasting state, apo A-IV concentrations were rather stable for 24 h, whereas triglycerides showed an increase over the daytime [between 1080 (530) and 1340 (690) mg/L], which correlated with apo A-IV (r ϭ 0.238; P Ͻ0.01). We found no circadian rhythm of apo A-IV concentrations in our study participants; however, the decrease in apo A-IV plasma concentrations during extended fasting periods took surprisingly long. The usual 10-to 12-h fasting periods before blood drawing for lipid evaluations do not appear to be sufficient to reach baseline apo A-IV concentrations. Therefore, apo A-IV requires well-defined protocols when this protein is studied.
